Navigation Links
Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
Date:4/29/2013

dy author. "These patients are in many ways more fragile, and at greater risk from spinal surgery, than patients with other types of diseases or injuries where our cell therapy may be applicable. That our cells and method of delivery are safe in ALS patients bodes very well for expanding to other indications. We expect to commence our FDA-approved Phase I trial in chronic spinal cord injury later this year using the same methodology. We want to thank the surgeons at Emory, who developed these techniques, as well as the patients and their families who have taken part in the trial."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in the las
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
2. Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention
3. Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
4. Neuralstem Secures $8 Million In Debt Financing From Hercules
5. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
6. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
7. Neuralstem to Raise $7.0 Million in Registered Direct Offering
8. Neuralstem Announces Proposed Public Offering
9. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
10. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
11. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... TOKYO , May 30, 2015  Astellas Pharma ... a Phase 1/2 trial on the safety, tolerability and ... patients with relapsed or refractory (R/R) acute myeloid leukemia ... the American Society of Clinical Oncology,s (ASCO) annual meeting ... is a receptor tyrosine kinase inhibitor of FLT3 and ...
(Date:5/30/2015)... Tex. , May 30, 2015 ... on fulfilling the promise of precision medicine, today ... that demonstrate the utility of Caris Molecular Intelligence®, ... facilitating comparisons between tumors that share histological features. ... the American Society of Clinical Oncology (ASCO) in ...
(Date:5/29/2015)... 2015  Excite Medical was established by its President, ... Excite Medical, under the leadership of Mr. Musallam ... a solid track record of providing unparalleled service and ... base.  Photo - http://photos.prnewswire.com/prnh/20150529/219412 ... been possible, in large part, due to Mr. ...
Breaking Medicine Technology:Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 2Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
(Date:5/30/2015)... Chicago, Ill. (PRWEB) May 30, 2015 ... academicians were recognized by their peers as the 2015 ... hosted by OncLive® at the Chicago Illuminating Company last ... panel of eminent oncologists for landmark achievements in translational ... has changed the course of cancer treatment. , Honorees ...
(Date:5/30/2015)... 2015 Thousands of aesthetic industry professionals ... sponsored by the American Society for Aesthetic Plastic Surgery ... was Zeltiq, the parent company of one of the ... With blazing growth, the one-of-a-kind device just sold its ... is currently in the news for gaining the FDA’s ...
(Date:5/30/2015)... 30, 2015 On Thursday, May ... Charles Simone and Dr. Evan Alley both of ... the Mesothelioma Experts’ series. The interview was part ... centers of excellence. Drs. Simone and Alley were ... Hesdorffer, with whom they discussed the mesothelioma program ...
(Date:5/30/2015)... Industry, CA (PRWEB) May 30, 2015 ... technology and foreign travelers who experienced OGAWA products while ... in the U.S. , A leader in the ... is a cutting-edge designer, researcher, developer and manufacturer of ... longevity and superior craftsmanship of their products, health enthusiasts ...
(Date:5/30/2015)... Cyclist Barry Haarde will commence his ... 2015: Piles of Miles” near San Francisco, California ... and encourage individuals to support needy hemophilic children ... Life supports nearly 1,200 impoverished children and adults ... sponsorships, scholarships and micro-enterprise grants. Hemophilia is a ...
Breaking Medicine News(10 mins):Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 2Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 4Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2
... placenta may damage blood vessels in women with preeclampsia ... to life-threatening increases in high blood pressure after 20 ... substances called "microparticles" released by the placenta damage maternal ... by Seth Guller, sought to detect whether specific proteins ...
... mutation that causes X-linked mental retardation for which there ... study. ,Investigators F. Lucy Raymond, ... Sanger Institute, UK describe the ZDHHC9 gene found in ... point of entirely losing function. ,"ZDHHC9 ...
... A new calibration technique that involves measuring the distance ... help facial plastic surgeons// use computer imaging software, according ... facial proportions has been studied for centuries by architects, ... information in the article. It is essential for plastic ...
... who treat them have incorporated spirituality into the recovery ... how spirituality changes during recovery, or how those changes ... quest for sobriety. ,Now, a new study ... Center sheds light on this phenomenon. In the March ...
... developed a malaria-resistant mosquito, a step that might one day ... millions// of lives around the world. ,When ... higher survival rate than nonresistant ones, meaning they could eventually ... a report in Tuesday's issue of Proceedings of the National ...
... by the National Aeronautics and Space Administration (NASA) has ... has been thinning// since early 1990s. ,Aerosols ... naturally, originating from volcanoes, dust storms, forest and grassland ... tend to cause cooling of the Earth's surface immediately ...
Cached Medicine News:Health News:Severe Mental Retardation Gene Mutation Identified 2Health News:Computer Imaging Assists With Facial Reconstructive Surgery 2Health News:Spirituality Increases as Alcoholics Recover 2Health News:Spirituality Increases as Alcoholics Recover 3Health News:Malaria-resistant Mosquito Developed 2
... laser beam is delivered through an ultra thin ... the operator full freedom of movement when performing ... with a wide range of handpieces. Handpieces ... mm and 16 mm. Straight and angled ...
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
... VERSASTEP™ Plus Short Instrument for ... ,The VERSASTEP™ Plus Short ... Length is a unique endoscopic ... in laparoscopic procedures. It is ...
... Autosuture™ Blunt Tip Trocar consists of a ... a valve body assembly. , ,The ... valve and seal to prevent gas leakage ... Autosuture™ Blunt Tip Trocar includes built-in converters ...
Medicine Products: